Rational management of iron-deficiency anaemia in inflammatory bowel disease

Nutrients

Volumn 10, Issue 1, 2018, Pages

  Nielsen, Ole Haagen ^a   Soendergaard, Christoffer ^a   Vikner, Malene Elbaek ^a   Weiss, Günter ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Anaemia; Crohn s disease; IBD; Iron deficiency; Therapy; Ulcerative colitis

Indexed keywords

FERRITIN; FERROPORTIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PLATELET DERIVED GROWTH FACTOR BB; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; IRON; TRANSFERRIN RECEPTOR;

BONE MARROW BIOPSY; CELL DIFFERENTIATION; CROHN DISEASE; DESQUAMATION; ERYTHROID PRECURSOR CELL; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON HOMEOSTASIS; IRON INTAKE; IRON THERAPY; MEAN CORPUSCULAR VOLUME; MENSTRUATION; PATHOPHYSIOLOGY; REVIEW; ULCERATIVE COLITIS; VITAMIN DEFICIENCY; BLOOD; CHRONIC DISEASE; COMPLICATION; DIETARY SUPPLEMENT; DISEASE MANAGEMENT; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOLECULAR WEIGHT; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DIETARY SUPPLEMENTS; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRITINS; HEPCIDINS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; MOLECULAR WEIGHT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 85040939169     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10010082     Document Type: Review

References (199)

1. Kassebaum, N.J., Jasrasaria, R., Naghavi, M., Wulf, S.K., Johns, N., Lozano, R., Regan, M., Weatherall, D., Chou, D.P., Eisele, T.P., et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014, 123, 615-624.
2. Iron Deficinecy Anemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Available online: http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf (accessed on 11 November 2017).
3. Gulmez, H., Akin, Y., Savas, M., Gulum, M., Ciftci, H., Yalcinkaya, S., Yeni, E. Impact of iron supplementation on sexual dysfunction of women with iron deficiency anemia in short term: A preliminary study. J. Sex. Med. 2014, 11, 1042-1046.
4. Haas, J.D., Brownlie, T. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J. Nutr. 2001, 131, 676S-688S.
5. McClung, J.P., Murray-Kolb, L.E. Iron nutrition and premenopausal women: Effects of poor iron status on physical and neuropsychological performance. Annu. Rev. Nutr. 2013, 33, 271-288.
6. Bresgen, N., Eckl, P.M. Oxidative stress and the homeodynamics of iron metabolism. Biomolecules 2015, 5, 808-847.
7. Filmann, N., Rey, J., Schneeweiss, S., Ardizzone, S., Bager, P., Bergamaschi, G., Koutroubakis, I., Lindgren, S., Morena, F.L., Moum, B., et al. Prevalence of anemia in inflammatory bowel diseases in european countries: A systematic review and individual patient data meta-analysis. Inflamm. Bowel Dis. 2014, 20, 936-945.
8. Fiorino, G., Allocca, M., Danese, S. Commentary: Anaemia in inflammatory bowel disease—The most common and ignored extra intestinal manifestation. Aliment. Pharmacol. Ther. 2014, 39, 227-228.
9. Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R., Ghosh, S., Wu, J.C.Y., Chan, F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018, 390, 2769-2778.
10. Eriksson, C., Cao, Y., Rundquist, S., Zhulina, Y., Henriksson, I., Montgomery, S., Halfvarson, J. Changes in medical management and colectomy rates: A population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010. Aliment. Pharmacol. Ther. 2017, 46, 897-898.
11. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46-54.
12. Kaplan, G.G., Jess, T. The Changing Landscape of Inflammatory Bowel Disease: East Meets West. Gastroenterology 2016, 150, 24-26.
13. Portela, F., Lago, P., Cotter, J., Goncalves, R., Vasconcelos, H., Ministro, P., Lopes, S., Eusebio, M., Morna, H., Cravo, M., et al. Anaemia in patients with inflammatory bowel disease—A nationwide cross-sectional study. Digestion 2016, 93, 214-220.
14. Hoivik, M.L., Reinisch, W., Cvancarova, M., Moum, B. Anaemia in inflammatory bowel disease: A population-based 10-year follow-up. Aliment. Pharmacol. Ther. 2014, 39, 69-76.
15. Azzopardi, N., Ellul, P. Iron deficiency in Crohn’s disease: Iron supplementation or disease control? J. Crohn’s Colitis 2014, 8, 1333.
16. Bager, P., Befrits, R., Wikman, O., Lindgren, S., Moum, B., Hjortswang, H., Dahlerup, J.F. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: A longitudinal 2-year follow-up study. Scand. J. Gastroenterol. 2013, 48, 1286-1293.
17. Gisbert, J.P., Gomollon, F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am. J. Gastroenterol. 2008, 103, 1299-1307.
18. Larsen, S., Bendtzen, K., Nielsen, O.H. Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management. Ann. Med. 2010, 42, 97-114.
19. Goodhand, J.R., Kamperidis, N., Rao, A., Laskaratos, F., McDermott, A., Wahed, M., Naik, S., Croft, N.M., Lindsay, J.O., Sanderson, I.R., et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm. Bowel Dis. 2012, 18, 513-519.
20. Vagianos, K., Clara, I., Carr, R., Graff, L.A., Walker, J.R., Targownik, L.E., Lix, L.M., Rogala, L., Miller, N., Bernstein, C.N. What are adults with inflammatory bowel disease IBeating? A closer look at the dietary habits of a population-based Canadian IBD cohort. J. Parenter. Enter. Nutr. 2015, 2016, 405-411.
21. Theurl, I., Aigner, E., Theurl, M., Nairz, M., Seifert, M., Schroll, A., Sonnweber, T., Eberwein, L., Witcher, D.R., Murphy, A.T., et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood 2009, 113, 5277-5286.
22. Weiss, G., Gasche, C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica 2010, 95, 175-178.
23. Hwang, C., Ross, V., Mahadevan, U. Micronutrient deficiencies in inflammatory bowel disease: From A to zinc. Inflamm. Bowel Dis. 2012, 18, 1961-1981.
24. Murawska, N., Fabisiak, A., Fichna, J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: Pathophysiology, diagnosis, and treatment. Inflamm. Bowel Dis. 2016, 22, 1198-1208.
25. Gasche, C., Berstad, A., Befrits, R., Beglinger, C., Dignass, A., Erichsen, K., Gomollon, F., Hjortswang, H., Koutroubakis, I., Kulnigg, S., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm. Bowel Dis. 2007, 13, 1545-1553.
26. Goldberg, N.D. Iron deficiency anemia in patients with inflammatory bowel disease. Clin. Exp. Gastroenterol. 2013, 6, 61-70.
27. Semrin, G., Fishman, D.S., Bousvaros, A., Zholudev, A., Saunders, A.C., Correia, C.E., Nemeth, E., Grand, R.J., Weinstein, D.A. Impaired intestinal iron absorption in Crohn’s disease correlates with disease activity and markers of inflammation. Inflamm. Bowel Dis. 2006, 12, 1101-1106.
28. Weiss, G., Goodnough, L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352, 1011-1023.
29. Weiss, G., Schett, G. Anaemia in inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 2013, 9, 205-215.
30. Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., Weiss, G. ‘Ride on the ferrous wheel’—The cycle of iron in macrophages in health and disease. Immunobiology 2015, 220, 280-294.
31. Camaschella, C. Iron-deficiency anemia. N. Engl. J. Med. 2015, 372, 1832-1843.
32. Shander, A., Goodnough, L.T., Javidroozi, M., Auerbach, M., Carson, J., Ershler, W.B., Ghiglione, M., Glaspy, J., Lew, I. Iron deficiency anemia-bridging the knowledge and practice gap. Transfus. Med. Rev. 2014, 28, 156-166.
33. Stein, J., Hartmann, F., Dignass, A.U. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 599-610.
34. Pizzi, L.T., Weston, C.M., Goldfarb, N.I., Moretti, D., Cobb, N., Howell, J.B., Infantolino, A., Dimarino, A.J., Cohen, S. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12, 47-52.
35. De Silva, A.D., Tsironi, E., Feakins, R.M., Rampton, D.S. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: A prospective, comparative trial. Aliment. Pharmacol. Ther. 2005, 22, 1097-1105.
36. Bager, P., Befrits, R., Wikman, O., Lindgren, S., Moum, B., Hjortswang, H., Hjollund, N.H., Dahlerup, J.F. Fatigue in out-patients with inflammatory bowel disease is common and multifactorial. Aliment. Pharmacol. Ther. 2012, 35, 133-141.
37. Gasche, C., Lomer, M.C., Cavill, I., Weiss, G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004, 53, 1190-1197.
38. Dignass, A.U., Gasche, C., Bettenworth, D., Birgegard, G., Danese, S., Gisbert, J.P., Gomollon, F., Iqbal, T., Katsanos, K., Koutroubakis, I., et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J. Crohn’s Colitis 2015, 9, 211-222.
39. Martin, J., Radeke, H.H., Dignass, A., Stein, J. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2017, 11, 19-32.
40. Stein, J., Bager, P., Befrits, R., Gasche, C., Gudehus, M., Lerebours, E., Magro, F., Mearin, F., Mitchell, D., Oldenburg, B., et al. Anaemia management in patients with inflammatory bowel disease: Routine practice across nine European countries. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1456-1463.
41. Hentze, M.W., Muckenthaler, M.U., Galy, B., Camaschella, C. Two to tango: Regulation of Mammalian iron metabolism. Cell 2010, 142, 24-38.
42. Zhang, C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 2014, 5, 750-760.
43. Pantopoulos, K., Porwal, S.K., Tartakoff, A., Devireddy, L. Mechanisms of mammalian iron homeostasis. Biochemistry 2012, 51, 5705-5724.
44. Coad, J., Conlon, C. Iron deficiency in women: Assessment, causes and consequences. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 625-634.
45. Andrews, N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341, 1986-1995.
46. McDermid, J.M., Lonnerdal, B. Iron. Adv. Nutr. 2012, 3, 532-533.
47. Hurrell, R., Egli, I. Iron bioavailability and dietary reference values. Am. J. Clin. Nutr. 2010, 91, 1461S-1467S.
48. Ganz, T., Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 2012, 1823, 1434-1443.
49. Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090-2093.
50. Ruchala, P., Nemeth, E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol. Sci. 2014, 35, 155-161.
51. Ganz, T., Nemeth, E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 2011, 62, 347-360.
52. Bregman, D.B., Morris, D., Koch, T.A., He, A., Goodnough, L.T. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. 2013, 88, 97-101.
53. Koskenkorva-Frank, T.S., Weiss, G., Koppenol, W.H., Burckhardt, S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med. 2013, 65, 1174-1194.
54. Carvalho, L., Brait, D., Vaz, M., Lollo, P., Morato, P., Oesterreich, S., Raposo, J., Freitas, K. Partially hydrolyzed guar gum increases ferroportin expression in the colon of anemic growing rats. Nutrients 2017, 9, 228.
55. Ludwiczek, S., Aigner, E., Theurl, I., Weiss, G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003, 101, 4148-4154.
56. Munoz, M., Garcia-Erce, J.A., Remacha, A.F. Disorders of iron metabolism. Part II: Iron deficiency and iron overload. J. Clin. Pathol. 2011, 64, 287-296.
57. Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., Eller, K., Wolf, D., Seifert, M., Sun, C.C., et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118, 4977-4984.
58. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E., Ganz, T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014, 46, 678-684.
59. Peyssonnaux, C., Zinkernagel, A.S., Schuepbach, R.A., Rankin, E., Vaulont, S., Haase, V.H., Nizet, V., Johnson, R.S. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig. 2007, 117, 1926-1932.
60. Sonnweber, T., Nachbaur, D., Schroll, A., Nairz, M., Seifert, M., Demetz, E., Haschka, D., Mitterstiller, A.M., Kleinsasser, A., Burtscher, M., et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 2014, 63, 1951-1959.
61. Tanno, T., Bhanu, N.V., Oneal, P.A., Goh, S.H., Staker, P., Lee, Y.T., Moroney, J.W., Reed, C.H., Luban, N.L., Wang, R.H., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 2007, 13, 1096-1101.
62. Theurl, I., Schroll, A., Nairz, M., Seifert, M., Theurl, M., Sonnweber, T., Kulaksiz, H., Weiss, G. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica 2011, 96, 1761-1769.
63. Lasocki, S., Baron, G., Driss, F., Westerman, M., Puy, H., Boutron, I., Beaumont, C., Montravers, P. Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia. Intensive Care Med. 2010, 36, 1044-1048.
64. Mullin, G.E. Micronutrients and inflammatory bowel disease. Nutr. Clin. Pract. 2012, 27, 136-137.
65. Thomas, C., Thomas, L. Anemia of chronic disease: Pathophysiology and laboratory diagnosis. Lab. Hematol. 2005, 11, 14-23.
66. Oldenburg, B., Koningsberger, J.C., Van Berge Henegouwen, G.P., Van Asbeck, B.S., Marx, J.J. Iron and inflammatory bowel disease. Aliment. Pharmacol. Ther. 2001, 15, 429-438.
67. Theurl, I., Mattle, V., Seifert, M., Mariani, M., Marth, C., Weiss, G. Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006, 107, 4142-4148.
68. Weiss, G. Anemia of chronic disorders: New diagnostic tools and new treatment strategies. Semin. Hematol. 2015, 52, 313-320.
69. Anker, S.D., Comin, C.J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Luscher, T.F., Bart, B., Banasiak, W., Niegowska, J., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 2009, 361, 2436-2448.
70. Jankowska, E.A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., Macdougall, I.C., Weiss, G., McMurray, J.J., Anker, S.D., et al. Iron status in patients with chronic heart failure. Eur. Heart J. 2013, 34, 827-834.
71. Cook, J.D. Diagnosis and management of iron-deficiency anaemia. Best Pract. Res. Clin. Haematol. 2005, 18, 319-332.
72. Arosio, P., Levi, S. Ferritin, iron homeostasis, and oxidative damage. Free Radic. Biol. Med. 2002, 33, 457-463.
73. Goddard, A.F., McIntyre, A.S., Scott, B.B. Guidelines for the management of iron deficiency anaemia. Gut 2000, 46, iv1-iv5.
74. Lipschitz, D.A., Cook, J.D., Finch, C.A. A clinical evaluation of serum ferritin as an index of iron stores. N. Engl. J. Med. 1974, 290, 1213-1216.
75. Mast, A.E., Blinder, M.A., Gronowski, A.M., Chumley, C., Scott, M.G. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin. Chem. 1998, 44, 45-51.
76. Van Santen, S., de Mast, Q., Oosting, J.D., van Ede, A., Swinkels, D.W., van der Ven, A.J.A.M. Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica 2014, 99, e171-e173.
77. Archer, N.M., Brugnara, C. Diagnosis of iron-deficient states. Crit. Rev. Clin. Lab. Sci. 2015, 52, 256-272.
78. Punnonen, K., Irjala, K., Rajamaki, A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997, 89, 1052-1057.
79. Tessitore, N., Solero, G.P., Lippi, G., Bassi, A., Faccini, G.B., Bedogna, V., Gammaro, L., Brocco, G., Restivo, G., Bernich, P., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol. Dial. Transplant. 2001, 16, 1416-1423.
80. Brugnara, C., Schiller, B., Moran, J. Reticulocyte hemoglobin equivalent Ret Hand assessment of iron-deficient states. Clin. Lab. Haematol. 2006, 28, 303-308.
81. Goodnough, L.T., Nemeth, E., Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010, 116, 4754-4761.
82. Van Santen, S., van Dongen-Lases, E.C., de Vegt, F., Laarakkers, C.M.M., van Riel, P.L.C.M., van Ede, A.E., Swinkels, D.W. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011, 63, 3672-3680.
83. Girelli, D., Nemeth, E., Swinkels, D.W. Hepcidin in the diagnosis of iron disorders. Blood 2016, 127, 2809-2813.
84. Prentice, A.M., Doherty, C.P., Abrams, S.A., Cox, S.E., Atkinson, S.H., Verhoef, H., Armitage, A.E., Drakesmith, H. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012, 119, 1922-1928.
85. Wilson, A., Reyes, E., Ofman, J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am. J. Med. 2004, 116, 44-49.
86. Gomollon, F., Gisbert, J.P., Garcia-Erce, J.A. Intravenous iron in digestive diseases: A clinical (re)view. Ther. Adv. Chronic Dis. 2010, 1, 67-75.
87. Klein, H.G., Spahn, D.R., Carson, J.L. Red blood cell transfusion in clinical practice. Lancet 2007, 370, 415-426.
88. Goodnough, L.T., Bach, R.G. Anemia, transfusion, and mortality. N. Engl. J. Med. 2001, 345, 1272-1274.
89. Villanueva, C., Colomo, A., Bosch, A., Concepcion, M., Hernandez-Gea, V., Aracil, C., Graupera, I., Poca, M., Alvarez-Urturi, C., Gordillo, J., et al. Transfusion strategies for acute upper gastrointestinal bleeding. N. Engl. J. Med. 2013, 368, 11-21.
90. Taylor, R.W., Manganaro, L., O’Brien, J., Trottier, S.J., Parkar, N., Veremakis, C. Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit. Care Med. 2002, 30, 2249-2254.
91. Talbot, T.R., D’Agata, E.M., Brinsko, V., Lee, B., Speroff, T., Schaffner, W. Perioperative blood transfusion is predictive of poststernotomy surgical site infection: Marker for morbidity or true immunosuppressant? Clin. Infect. Dis. 2004, 38, 1378-1382.
92. Aubron, C., Nichol, A., Cooper, D.J., Bellomo, R. Age of red blood cells and transfusion in critically ill patients. Ann. Intensive Care 2013, 3.
93. Bihl, F., Castelli, D., Marincola, F., Dodd, R.Y., Brander, C. Transfusion-transmitted infections. J. Transl. Med. 2007, 5, 25.
94. Guinet, F., Carniel, E., Leclercq, A. Transfusion-transmitted Yersinia enterocolitica sepsis. Clin. Infect. Dis. 2011, 53, 583-591.
95. Cancelo-Hidalgo, M.J., Castelo-Branco, C., Palacios, S., Haya-Palazuelos, J., Ciria-Recasens, M., Manasanch, J., Perez-Edo, L. Tolerability of different oral iron supplements: A systematic review. Curr. Med. Res. Opin. 2013, 29, 291-303.
96. Santiago, P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: A clinical overview. Sci. World J. 2012.
97. Fuqua, B.K., Vulpe, C.D., Anderson, G.J. Intestinal iron absorption. J. Trace Elem. Med. Biol. 2012, 26, 115-119.
98. Aspuru, K., Villa, C., Bermejo, F., Herrero, P., Lopez, S.G. Optimal management of iron deficiency anemia due to poor dietary intake. Int. J. Gen. Med. 2011, 4, 741-750.
99. Lane, D.J., Richardson, D.R. The active role of vitamin C in mammalian iron metabolism: Much more than just enhanced iron absorption! Free Radic. Biol. Med. 2014, 75, 69-83.
100. Syed, S., Michalski, E.S., Tangpricha, V., Chesdachai, S., Kumar, A., Prince, J., Ziegler, T.R., Suchdev, P.S., Kugathasan, S. Vitamin D Status is associated with hepcidin and hemoglobin concentrations in children with inflammatory bowel disease. Inflamm. Bowel Dis. 2017, 23, 1650-1658.
101. Mouli, V.P., Ananthakrishnan, A.N. Review article: Vitamin D and inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2014, 39, 125-136.
102. Bacchetta, J., Zaritsky, J.J., Sea, J.L., Chun, R.F., Lisse, T.S., Zavala, K., Nayak, A., Wesseling-Perry, K., Westerman, M., Hollis, B.W., et al. Suppression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol. 2014, 25, 564-572.
103. Gubatan, J., Mitsuhashi, S., Zenlea, T., Rosenberg, L., Robson, S., Moss, A.C. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 2017, 15, 240-246.
104. Kabbani, T.A., Koutroubakis, I.E., Schoen, R.E., Ramos-Rivers, C., Shah, N., Swoger, J., Regueiro, M., Barrie, A., Schwartz, M., Hashash, J.G., et al. Association of vitamin D level with clinical status in inflammatory bowel disease: A 5-year longitudinal study. Am. J. Gastroenterol. 2016, 111, 712-719.
105. Winter, R.W., Collins, E., Cao, B., Carrellas, M., Crowell, A.M., Korzenik, J.R. Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases. Aliment. Pharmacol. Ther. 2017, 45, 653-659.
106. Smith, E.M., Tangpricha, V. Vitamin D and anemia: Insights into an emerging association. Curr. Opin. Endocrinol. Diabetes Obes. 2015, 22, 432-438.
107. Smith, E.M., Jones, J.L., Han, J.E., Alvarez, J.A., Sloan, J.H., Konrad, R.J., Zughaier, S.M., Martin, G.S., Ziegler, T.R., Tangpricha, V. High-dose vitamin D3 administration is associated with increases in hemoglobin concentrations in mechanically ventilated critically III adults: A pilot double-blind, randomized, placebo-controlled trial. J. Parenter. Enter. Nutr. 2018.
108. Zughaier, S.M., Alvarez, J.A., Sloan, J.H., Konrad, R.J., Tangpricha, V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J. Clin. Transl. Endocrinol. 2014, 1, 19-25.
109. Smith, E.M., Alvarez, J.A., Kearns, M.D., Hao, L., Sloan, J.H., Konrad, R.J., Ziegler, T.R., Zughaier, S.M., Tangpricha, V. High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. Clin. Nutr. 2017, 36, 980-985.
110. Gasche, C., Ahmad, T., Tulassay, Z., Baumgart, D.C., Bokemeyer, B., Buning, C., Howaldt, S., Stallmach, A. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program. Inflamm. Bowel Dis. 2015, 21, 579-588.
111. Hallberg, L., Ryttinger, L., Solvell, L. Side-effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. J. Intern. Med. 1966, 180, 3-10.
112. Moretti, D., Goede, J.S., Zeder, C., Jiskra, M., Chatzinakou, V., Tjalsma, H., Melse-Boonstra, A., Brittenham, G., Swinkels, D.W., Zimmermann, M.B. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015, 126, 1981-1989.
113. Stoffel, N.U., Cercamondi, C.I., Brittenham, G., Zeder, C., Geurts-Moespot, A.J., Swinkels, D.W., Moretti, D., Zimmermann, M.B. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: Two open-label, randomised controlled trials. Lancet Haematol. 2017, 4, e524-e533.
114. Kulnigg, S., Gasche, C. Systematic review: Managing anaemia in Crohn’s disease. Aliment. Pharmacol. Ther. 2006, 24, 1507-1523.
115. Iqbal, T., Stein, J., Sharma, N., Kulnigg-Dabsch, S., Vel, S., Gasche, C. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia. Dig. Dis. Sci. 2015, 60, 1375-1381.
116. Erichsen, K., Milde, A.M., Arslan, G., Helgeland, L., Gudbrandsen, O.A., Ulvik, R.J., Berge, R.K., Hausken, T., Berstad, A. Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm. Bowel Dis. 2005, 11, 744-748.
117. Rizvi, S., Schoen, R.E. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: Is oral iron getting a bad rap? Am. J. Gastroenterol. 2011, 106, 1872-1879.
118. Lee, T., Clavel, T., Smirnov, K., Schmidt, A., Lagkouvardos, I., Walker, A., Lucio, M., Michalke, B., Schmitt-Kopplin, P., Fedorak, R., et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017, 66, 863-871.
119. Lee, T.W., Kolber, M.R., Fedorak, R.N., van Zanten, S.V. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. J. Crohn’s Colitis 2012, 6, 267-275.
120. Kostic, A.D., Xavier, R.J., Gevers, D. The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology 2014, 146, 1489-1499.
121. Werner, T., Wagner, S.J., Martinez, I., Walter, J., Chang, J.S., Clavel, T., Kisling, S., Schuemann, K., Haller, D. Depletion of luminal iron alters the gut microbiota and prevents Crohn’s disease-like ileitis. Gut 2011, 60, 325-333.
122. Kulnigg, S., Teischinger, L., Dejaco, C., Waldhor, T., Gasche, C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am. J. Gastroenterol. 2009, 104, 1460-1467.
123. Vadhan-Raj, S., Strauss, W., Ford, D., Bernard, K., Boccia, R., Li, J., Allen, L.F. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am. J. Hematol. 2014, 89, 7-12.
124. New recommendations to manage risk of allergic reactions with intravenous iron-containing Medicines. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001833.jspandmid=WC0b01ac058004d5c1 (accessed on 27 November 2017).
125. Highlights of prescription information. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203565s000lbl.pdf (accessed on 7 November 2017).
126. Auerbach, M., Rodgers, G.M. Intravenous iron. N. Engl. J. Med. 2007, 357, 93-94.
127. Rampton, D., Folkersen, J., Fishbane, S., Hedenus, M., Howaldt, S., Locatelli, F., Patni, S., Szebeni, J., Weiss, G. Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologia 2014, 99, 1671-1676.
128. Gisbert, J.P., Bermejo, F., Pajares, R., Perez-Calle, J.L., Rodriguez, M., Algaba, A., Mancenido, N., de la Morena, F., Carneros, J.A., McNicholl, A.G., et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm. Bowel Dis. 2009, 15, 1485-1491.
129. Reinisch, W., Staun, M., Tandon, R.K., Altorjay, I., Thillainayagam, A.V., Gratzer, C., Nijhawan, S., Thomsen, L.L. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1000 Monofecompared with oral iron for treatment of anemia in IBD (PROCEED). Am. J. Gastroenterol. 2013, 108, 1877-1888.
130. Auerbach, M., Ballard, H. Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology. ASH Educ. Program Book 2010, 2010, 338-347.
131. Gomollon, F., Gisbert, J.P. Intravenous iron in inflammatory bowel diseases. Curr. Opin. Gastroenterol. 2013, 29, 201-207.
132. Gomollon, F., Chowers, Y., Danese, S., Dignass, A., Nielsen, O.H., Lakatos, P.L., Lees, C.W., Lindgren, S., Lukas, M., Mantzaris, G.J., et al. Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. Aliment. Pharmacol. Ther. 2014, 39, 743-744.
133. Chertow, G.M., Mason, P.D., Vaage-Nilsen, O., Ahlmen, J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 2006, 21, 378-382.
134. Khalil, A., Goodhand, J.R., Wahed, M., Yeung, J., Ali, F.R., Rampton, D.S. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: A case-matched study in clinical practice. Eur. J. Gastroenterol. Hepatol. 2011, 23, 1029-1035.
135. Koutroubakis, I.E., Oustamanolakis, P., Karakoidas, C., Mantzaris, G.J., Kouroumalis, E.A. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig. Dis. Sci. 2010, 55, 2327-2331.
136. Rodgers, G.M., Auerbach, M., Cella, D., Chertow, G.M., Coyne, D.W., Glaspy, J.A., Henry, D.H. High-molecular weight iron dextran: A wolf in sheep’s clothing? J. Am. Soc. Nephrol. 2008, 19, 833-834.
137. Auerbach, M., Pappadakis, J.A., Bahrain, H., Auerbach, S.A., Ballard, H., Dahl, N.V. Safety and efficacy of rapidly administered one houone gram of low molecular weight iron dextran INFefor the treatment of iron deficient anemia. Am. J. Hematol. 2011, 86, 860-862.
138. Schroder, O., Mickisch, O., Seidler, U., de Weerth, A., Dignass, A.U., Herfarth, H., Reinshagen, M., Schreiber, S., Junge, U., Schrott, M., et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—A randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol. 2005, 100, 2503-2509.
139. Reed, J. Reed Book: Pharmacy’s Fundamental Reference, 114th ed., Thompson Reuters: Montvale, NJ, USA, 2010, pp. 1-900.
140. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., Cabantchik, Z.I. Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 2003, 102, 2670-2677.
141. Beigel, F., Lohr, B., Laubender, R.P., Tillack, C., Schnitzler, F., Breiteneicher, S., Weidinger, M., Goke, B., Seiderer, J., Ochsenkuhn, T., et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2012, 85, 47-54.
142. Evstatiev, R., Marteau, P., Iqbal, T., Khalif, I.L., Stein, J., Bokemeyer, B., Chopey, I.V., Gutzwiller, F.S., Riopel, L., Gasche, C. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011, 141, 846-853.
143. Evstatiev, R., Alexeeva, O., Bokemeyer, B., Chopey, I., Felder, M., Gudehus, M., Iqbal, T., Khalif, I., Marteau, P., Stein, J., et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013, 11, 269-277.
144. Kulnigg, S., Stoinov, S., Simanenkov, V., Dudar, L.V., Karnafel, W., Garcia, L.C., Sambuelli, A.M., D’Haens, G., Gasche, C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose FERINJECrandomized controlled trial. Am. J. Gastroenterol. 2008, 103, 1182-1192.
145. Onken, J.E., Bregman, D.B., Harrington, R.A., Morris, D., Acs, P., Akright, B., Barish, C., Bhaskar, B.S., Smith-Nguyen, G.N., Butcher, A., et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014, 54, 306-315.
146. Gozzard, D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des. Dev. Ther. 2011, 5, 51-60.
147. Nordfjeld, K., Andreasen, H., Thomsen, L.L. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des. Dev. Ther. 2012, 6, 43-51.
148. Auerbach, M., Strauss, W., Auerbach, S., Rineer, S., Bahrain, H. Safety and efficacy of total dose infusion of 1020 mg of ferumoxytol administered over 15 min. Am. J. Hematol. 2013, 88, 944-947.
149. Ford, D.C., Dahl, N.V., Strauss, W.E., Barish, C.F., Hetzel, D.J., Bernard, K., Li, Z., Allen, L.F. Ferumoxytol versus placebo in iron deficiency anemia: Efficacy, safety, and quality of life in patients with gastrointestinal disorders. Clin. Exp. Gastroenterol. 2016, 9, 151-162.
150. Schieda, N. Parenteral ferumoxytol interaction with magnetic resonance imaging: A case report, review of the literature and advisory warning. Insights Imaging 2013, 4, 509-512.
151. Bailie, G.R. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am. J. Health Syst. Pharm. 2012, 69, 310-320.
152. Szebeni, J., Fishbane, S., Hedenus, M., Howaldt, S., Locatelli, F., Patni, S., Rampton, D., Weiss, G., Folkersen, J. Hypersensitivity to intravenous iron: Classification, terminology, mechanisms and management. Br. J. Pharmacol. 2015, 172, 5025-5028.
153. Auerbach, M., Ballard, H., Glaspy, J. Clinical update: Intravenous iron for anaemia. Lancet 2007, 369, 1502-1504.
154. Chertow, G.M., Winkelmayer, W.C. On the relative safety of intravenous iron formulations: New answers, new questions. Am. J. Hematol. 2010, 85, 643-644.
155. Fishbane, S., Ungureanu, V.D., Maesaka, J.K., Kaupke, C.J., Lim, V., Wish, J. The safety of intravenous iron dextran in hemodialysis patients. Am. J. Kidney Dis. 1996, 28, 529-534.
156. Auerbach, M., Coyne, D., Ballard, H. Intravenous iron: From anathema to standard of care. Am. J. Hematol. 2008, 83, 580-588.
157. Boyce, M., Warrington, S., Cortezi, B., Zollner, S., Vauleon, S., Swinkels, D.W., Summo, L., Schwoebel, F., Riecke, K. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer Lexaptepid pegol in healthy subjects. Br. J. Pharmacol. 2016, 173, 1580-1588.
158. Cooke, K.S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., Winters, A., Steavenson, S., Begley, C.G., Molineux, G., et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013, 122, 3054-3061.
159. Sebastiani, G., Wilkinson, N., Pantopoulos, K. Pharmacological targeting of the hepcidin/ferroportin axis. Front. Pharmacol. 2016, 7, 160-170.
160. Sun, C.C., Vaja, V., Chen, S., Theurl, I., Stepanek, A., Brown, D.E., Cappellini, M.D., Weiss, G., Hong, C.C., Lin, H.Y., et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol. Dial. Transplant. 2013, 28, 1733-1743.
161. Gupta, N., Wish, J.B. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am. J. Kidney Dis. 2017, 69, 815-826.
162. Haase, V.H. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial. Int. 2017, 21, S110-S124.
163. Simpson, R.J., McKie, A.T. Iron and oxygen sensing: A tale of 2 interacting elements? Metallomics 2015, 7, 223-231.
164. Nielsen, O.H., Ainsworth, M., Coskun, M., Weiss, G. Management of iron-deficiency anemia in inflammatory bowel disease: A systematic review. Medicine 2015, 94, e963-e976.
165. Lindgren, S., Wikman, O., Befrits, R., Blom, H., Eriksson, A., Granno, C., Ung, K.A., Hjortswang, H., Lindgren, A., Unge, P. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand. J. Gastroenterol. 2009, 44, 838-845.
166. Litton, E., Xiao, J., Ho, K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013, 347, f4822.
167. Fishbane, S. Balance of benefit and risk in intravenous iron treatment in chronic kidney disease. Semin. Nephrol. 2016, 36, 119-123.
168. Li, X., Kshirsagar, A.V., Brookhart, M.A. Safety of intravenous iron in hemodialysis patients. Hemodial. Int. 2017, 21, S93-S103.
169. Macdougall, I.C., Bircher, A.J., Eckardt, K.U., Obrador, G.T., Pollock, C.A., Stenvinkel, P., Swinkels, D.W., Wanner, C., Weiss, G., Chertow, G.M. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” KDIGControversies Conference. Kidney Int. 2016, 89, 28-39.
170. Miskulin, D.C., Tangri, N., Bandeen-Roche, K., Zhou, J., McDermott, A., Meyer, K.B., Ephraim, P.L., Michels, W.M., Jaar, B.G., Crews, D.C., et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 2014, 9, 1930-1939.
171. Zitt, E., Sturm, G., Kronenberg, F., Neyer, U., Knoll, F., Lhotta, K., Weiss, G. Iron supplementation and mortality in incident dialysis patients: An observational study. PLoS ONE 2014, 9.
172. Aksan, A., Isik, H., Radeke, H.H., Dignass, A., Stein, J. Systematic review with network meta-analysis: Comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017, 45, 1303-1318.
173. Gonzalez, A.C., Pedrajas, C.C., Marin, P.S., Benitez, J.M., Iglesias, F.E., Salgueiro, R., Medina, M.R., Garcia-Sanchez, V. Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life. Gastroenterol. Hepatol. 2017.
174. Krayenbuehl, P.A., Battegay, E., Breymann, C., Furrer, J., Schulthess, G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011, 118, 3222-3227.
175. Cekic, C., Iepk, S., Aslan, F., Akpinat, Z., Arabul, M., Topal, F., Saritas-Yüksel, E., Alper, E., Ünsal, B. The effect of intravenous iron treatment on quality of life in inflammatory bowel disease patients with nonanemic iron deficiency. Gastroenterol. Res. Pract. 2015, 2015.
176. Eliadou, E., Kini, G., Huang, J., Champion, A., Inns, S.J. Intrevenous iron replacement improves quality of life in hypoferritinemic inflammatory bowel disease patients with and without anemia. Dig. Dis. 2017, 35, 444-448.
177. Favrat, B., Balck, K., Breymann, C., Hedenus, M., Keller, T., Mezzacasa, A., Gasche, C. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PLoS ONE 2014, 9, e94217.
178. Volani, C., Doerrier, C., Demetz, E., Haschka, D., Paglia, G., Lavdas, A.A., Gnaiger, E., Weiss, G. Dietary iron loading negatively affects liver mitochondrial function. Metallomics 2017, 9, 1634-1644.
179. Nielsen, O.H., Coskun, M., Weiss, G. Iron replacement therapy: Do we need new guidelines? Curr. Opin. Gastroenterol. 2016, 32, 128-135.
180. Rimon, E., Kagansky, N., Kagansky, M., Mechnick, L., Mashiah, T., Namir, M., Levy, S. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am. J. Med. 2005, 118, 1142-1147.
181. Ganzoni, A.M. Intravenous iron-dextran: Therapeutic and experimental possibilities. Schweiz. Med. Wochenschr. 1970, 100, 301-303.
182. Reinisch, W., Chowers, Y., Danese, S., Dignass, A., Gomollon, F., Nielsen, O.H., Lakatos, P.L., Lees, C.W., Lindgren, S., Lukas, M., et al. The management of iron deficiency in inflammatory bowel disease—An online tool developed by the RAND/UCLA appropriateness method. Aliment. Pharmacol. Ther. 2013, 38, 1109-1118.
183. Katsanos, K.H., Tatsioni, A., Natsi, D., Sigounas, D., Christodoulou, D.K., Tsianos, E.V. Recombinant human erythropoietin in patients with inflammatory bowel disease and refractory anemia: A 15-year single center experience. J. Crohn’s Colitis 2012, 6, 56-61.
184. Liu, S., Ren, J., Hong, Z., Yan, D., Gu, G., Han, G., Wang, G., Ren, H., Chen, J., Li, J. Efficacy of erythropoietin combined with enteral nutrition for the treatment of anemia in Crohn’s disease: A prospective cohort study. Nutr. Clin. Pract. 2013, 28, 120-127.
185. Solomon, S.D., Uno, H., Lewis, E.F., Eckardt, K.U., Lin, J., Burdmann, E.A., de Zeeuw, D., Ivanovich, P., Levey, A.S., Parfrey, P., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 2010, 363, 1146-1155.
186. Drueke, T.B., Parfrey, P.S. Summary of the KDIGO guideline on anemia and comment: Reading between the (guide)line(s). Kidney Int. 2012, 82, 952-960.
187. Sonnweber, T., Theurl, I., Seifert, M., Schroll, A., Eder, S., Mayer, G., Weiss, G. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol. Dial. Transplant. 2011, 26, 977-987.
188. Weiss, G., Carver, P.L. Role of divalent metals in infectious disease susceptibility and outcome. Clin. Microbiol. Infect. 2018, 24, 16-23.
189. Sazawal, S., Black, R.E., Ramsan, M., Chwaya, H.M., Stoltzfus, R.J., Dutta, A., Dhingra, U., Kabole, I., Deb, S., Othman, M.K., et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 2006, 367, 133-143.
190. Soofi, S., Cousens, S., Iqbal, S.P., Akhund, T., Khan, J., Ahmed, I., Zaidi, A.K., Bhutta, Z.A. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: A cluster-randomised trial. Lancet 2013, 382, 29-40.
191. Besarab, A., Bolton, W.K., Browne, J.K., Egrie, J.C., Nissenson, A.R., Okamoto, D.M., Schwab, S.J., Goodkin, D.A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998, 339, 584-590.
192. Locatelli, F., Pisoni, R.L., Combe, C., Bommer, J., Andreucci, V.E., Piera, L., Greenwood, R., Feldman, H.I., Port, F.K., Held, P.J. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004, 19, 121-132.
193. Bircher, A.J., Auerbach, M. Hypersensitivity from intravenous iron products. Immunol. Allergy Clin. 2014, 34, 707-723.
194. Schaefer, B., Wurtinger, P., Finkenstedt, A., Braithwaite, V., Viveiros, A., Effenberger, M., Sulzbacher, I., Moschen, A., Griesmacher, A., Tilg, H., et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE 2016, 11, e0167146.
195. Goldsmith, J.R., Sartor, R.B. The role of diet on intestinal microbiota metabolism: Downstream impacts on host immune function and health, and therapeutic implications. J. Gastroenterol. 2014, 49, 785-798.
196. Oustamanolakis, P., Koutroubakis, I.E., Messaritakis, I., Malliaraki, N., Sfiridaki, A., Kouroumalis, E.A. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2011, 23, 262-268.
197. Ganz, T. Systemic iron homeostasis. Physiol. Rev. 2013, 93, 1721-1741.
198. Katsanos, K., Cavalier, E., Ferrante, M., Van Hauwaert, V., Henckaerts, L., Schnitzler, F., Katsaraki, A., Noman, M., Vermeire, S., Tsianos, E.V., et al. Intravenous iron therapy restores functional iron deficiency induced by infliximab. J. Crohn’s Colitis 2007, 1, 97-105.
199. Nielsen, O.H., Ainsworth, M.A. Tumor necrosis factor inhibitors for inflammatory bowel disease. N. Engl. J. Med. 2013, 369, 754-762.